Athira Pharma announced the promotion of Kevin Church, Ph.D., to Chief Scientific Officer. "Kevin is a driving force behind our research at Athira. He is instrumental in leading and directing our efforts to elucidate and validate the promise of the HGF/MET pathway and its potential applications for the treatment of neurodegenerative disorders," said Mark Litton, Ph.D., President and CEO of Athira. "Kevin’s leadership and dedication to exploring novel approaches is guided by an unwavering commitment to innovation and integrity that resonates not only within the research team but throughout the company." Dr. Church joined Athira in 2016 and most recently served as Executive Vice President, Research.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATHA:
- Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
- Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
- Athira Pharma provides 2023 pipeline outlook
- Fly Insider: Terns Pharma, Best Buy among week’s notable insider trades
- Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
